Top Large-Cap Pharma Stocks Compared: Dr Reddy’s Laboratories vs Lupin vs Zydus Lifesciences vs Biocon vs Abbott India on Price, Valuation, Q2 FY27 Results and Risks
- November 12, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Previous close: Dr Reddy’s Laboratories Rs 1,377.00, Lupin Rs 2,023.40, Zydus Lifesciences Rs 1,199.50, Biocon Rs 368.05, Abbott India Rs 26,110.00.
Quick Answer
This large-cap pharma stocks compared snapshot checks five names on price, valuation and Q2 FY27 results: Dr Reddy’s Laboratories, Lupin, Zydus Lifesciences, Biocon and Abbott India. Zydus Lifesciences is the largest by market capitalisation at Rs 1,18,713 crore. Abbott India reports the highest return on equity at 38.71%. Premium multiples are common among pharma majors, so check whether returns and launches support each one.
Large-cap pharma stocks compared here means Dr Reddy’s Laboratories, Lupin, Zydus Lifesciences, Biocon and Abbott India on one page, checked on previous close, market value, valuation and the latest quarterly numbers. The group mixes a global generics and branded medicines maker, a respiratory and generics player, a maker of generics, vaccines and consumer products, a biosimilars specialist and a branded medicines seller in India, so each name earns from a different product set, which is exactly why a side-by-side look helps.
Dr Reddy’s Laboratories, Lupin, Zydus Lifesciences and Biocon have filed their September 2026 quarter, so their results below are Q2 FY27. Abbott India is tracked on price and valuation. Pharma names follow regulatory approvals, pricing in key markets and product launches, so a glance at the Nifty Pharma page and the Sensex page before you read the tables gives useful backdrop.
Click Here – Get Free Investment Predictions
Large-Cap Pharma Stocks Compared: Five Drug Majors
The large-cap pharma stocks compared here are Dr Reddy’s Laboratories, Lupin, Zydus Lifesciences, Biocon and Abbott India. Zydus Lifesciences is the largest by market capitalisation at Rs 1,18,713 crore. Previous closes run from Rs 368.05 for Biocon to Rs 26,110.00 for Abbott India, which is why a side-by-side look at value rather than price is more useful. This large-cap pharma stocks compared list is the base for every table that follows.
| Stock | Previous close (Rs) | Market cap (Rs crore) |
|---|---|---|
| Dr Reddy’s Laboratories | 1,377.00 | 1,14,933 |
| Lupin | 2,023.40 | 92,419 |
| Zydus Lifesciences | 1,199.50 | 1,18,713 |
| Biocon | 368.05 | 59,956 |
| Abbott India | 26,110.00 | 55,463 |
A quick look at the business behind each ticker puts the numbers in context. Dr Reddy’s Laboratories makes generics, branded medicines and active ingredients for global markets, while Lupin makes generics, branded medicines and respiratory products for many markets. Zydus Lifesciences makes generics, branded medicines, vaccines and consumer products, and Biocon makes biosimilars, generics and active ingredients and offers research services. To compare large-cap pharma stocks properly, line up price to earnings, return on equity and dividend yield before forming a view.
Rounding out the group, Abbott India sells branded medicines in India across many therapy areas. A fair large-cap pharma stock comparison looks at what each company actually earns from, not only at the share price. Global generics makers, biosimilars specialists and domestic brand sellers belong in separate mental boxes whenever you compare large-cap pharma stocks fairly.
Large-Cap Pharma Stocks Valuation: Multiples, Returns and Payouts
Lupin trades at the lowest price to earnings ratio in this group at 17.70. Abbott India reports the highest return on equity at 38.71%. Biocon has the lowest price to book value at 1.72. These large-cap pharma stocks valuation readings come from the previous close and the latest reported financials. That is the idea behind this large-cap pharma stocks compared table: price to earnings and return on equity sit side by side so a high or low reading stands out at once.
| Stock | Price to earnings | Price to book | ROE (%) | Dividend yield (%) | Debt to equity |
|---|---|---|---|---|---|
| Dr Reddy’s Laboratories | 41.65 | 2.96 | 7.21 | 0.58 | 0.19 |
| Lupin | 17.70 | 3.84 | 21.65 | 0.89 | 0.26 |
| Zydus Lifesciences | 27.59 | 4.27 | 15.10 | 0.08 | 0.50 |
| Biocon | 176.03 | 1.72 | 1.96 | 0.14 | 0.45 |
| Abbott India | 33.56 | 12.99 | 38.71 | 2.51 | 0.04 |
Large-cap pharma stocks often trade at premium price to earnings multiples because scale and approvals support steady earnings. Price to book, return on equity and dividend yield help you judge how the market values each company and how much it pays back. Earnings per share and book value per share are the building blocks behind price to earnings and price to book, so a glance at both in each filing is time well spent. A simple large-cap pharma stock comparison like this one is only as useful as the context behind it, which is why dividend yield is worth checking as well.
In this group, price to earnings runs from 17.70 for Lupin to 176.03 for Biocon. Abbott India offers the highest dividend yield at 2.51%. Industry price to earnings readings differ by sub-sector: Dr Reddy’s Laboratories, Lupin, Zydus Lifesciences and Biocon at 40.71; Abbott India at 52.37. The industry price to earnings is a handy anchor: a stock above it is priced for faster growth, and one below it is priced for steadier earnings. A well-built large-cap pharma stock comparison also notes that launches and currency moves can shift results between quarters. Run the same large-cap pharma stock comparison on your own watchlist and the pattern in these numbers will be easier to spot.
Large-Cap Pharma Stocks Q2 FY27 Results: Revenue and Profit Check
Four of the five large-cap pharma stocks compared have filed Q2 FY27 numbers. Zydus Lifesciences posted the fastest revenue growth at 29.0% year on year. Read revenue first and quarterly profit second, since the two together show how much of the growth reaches shareholders. The others are shown on their latest reported quarter, so read each one for what it is. Treat the Q2 FY27 numbers in this large-cap pharma stocks compared review as a snapshot of one quarter, not a verdict on any drug maker.
| Stock | Q2 FY27 revenue (Rs crore) | Q2 FY26 revenue (Rs crore) | Q2 FY27 net profit (Rs crore) | Q2 FY26 net profit (Rs crore) |
|---|---|---|---|---|
| Dr Reddy’s Laboratories | 8,854 | 9,152 | ||
| Lupin | 7,954 | 7,138 | ||
| Zydus Lifesciences | 8,040 | 6,232 | ||
| Biocon | 4,423 | 4,388 |
Dr Reddy’s Laboratories Results Snapshot
Dr Reddy’s Laboratories’ Q2 FY27 top line stood at Rs 8,854 crore.
Lupin Results Snapshot
Lupin reported Q2 FY27 revenue of Rs 7,954 crore, compared with Rs 7,138 crore a year earlier, a rise of 11.4%.
Zydus Lifesciences Results Snapshot
In the September 2026 quarter, Zydus Lifesciences booked revenue of Rs 8,040 crore against Rs 6,232 crore in the same quarter last year, a rise of 29.0%.
Biocon Results Snapshot
Biocon’s Q2 FY27 top line stood at Rs 4,423 crore, versus Rs 4,388 crore in Q2 FY26, a rise of 0.8%.
Abbott India Results Snapshot
Abbott India is tracked here on price and valuation. Its quarterly filing on the exchange website carries the revenue and profit detail, so read it before you set the stock against the rest.
Pharma results depend on product launches, approvals, pricing and the mix between generics and branded sales, so profit can look different from revenue in a single quarter. That is why a large-cap pharma stock comparison works best when revenue and profit are read together across two or three quarters. Used this way, a large-cap pharma stocks compared review becomes a map of the sector rather than a price list. When you compare large-cap pharma stocks after each result season, track how dividend yield changes from one quarter to the next.
Large-Cap Pharma Stocks Compared Two at a Time: Three Pairings
Readers rarely want a five-way table and nothing else, so here are three head-to-head reads drawn from the same data. Use them as a quick way to compare large-cap pharma stocks two at a time.
Dr Reddy’s Laboratories vs Lupin
Dr Reddy’s Laboratories and Lupin both make generics and branded medicines for many global markets, so they are the closest pair on the list. The two are close in size, with market capitalisations of Rs 1,14,933 crore for Dr Reddy’s Laboratories and Rs 92,419 crore for Lupin. Lupin reports the higher return on equity, at 21.65% against 7.21% for Dr Reddy’s Laboratories. For dividend income, Lupin offers 0.89% against 0.58% at Dr Reddy’s Laboratories. Both depend on approvals and launches, so read growth next to valuation before you judge either multiple.
Zydus Lifesciences vs Biocon
Zydus Lifesciences spans generics, vaccines and consumer products, while Biocon focuses on biosimilars, generics and research services. Zydus Lifesciences is about 2.0 times the size of Biocon by market capitalisation, at Rs 1,18,713 crore against Rs 59,956 crore. On price to earnings, Zydus Lifesciences carries the lower multiple at 27.59 against 176.03 for Biocon. Zydus Lifesciences reports the higher return on equity, at 15.10% against 1.96% for Biocon. A broad maker and a biosimilars specialist are priced differently, so read the business mix before you read the ratio.
Abbott India vs Dr Reddy’s Laboratories
Abbott India sells branded medicines in India, while Dr Reddy’s Laboratories earns across global generics and branded markets. On price to earnings, Abbott India carries the lower multiple at 33.56 against 41.65 for Dr Reddy’s Laboratories. Abbott India reports the higher return on equity, at 38.71% against 7.21% for Dr Reddy’s Laboratories. For dividend income, Abbott India offers 2.51% against 0.58% at Dr Reddy’s Laboratories. A domestic brand seller and a global maker earn differently, so read returns and valuation together.
Best Large-Cap Pharma Stocks for Each Type of Investor
If you are asking which of the best large-cap pharma stocks here suits you, the answer depends on what you value. The table below shows who leads on each measure today, which is the fairest way to answer without naming a single winner. Any large-cap pharma stocks compared table can mislead if you stop at one row, because each drug maker leads on a different measure.
| If you care most about | Start your research with | The number |
|---|---|---|
| Lowest price to earnings | Lupin | 17.70 |
| Highest return on equity | Abbott India | 38.71% |
| Highest dividend yield | Abbott India | 2.51% |
| Lowest price to book value | Biocon | 1.72 |
| Largest by market capitalisation | Zydus Lifesciences | Rs 1,18,713 crore |
| Fastest Q2 FY27 revenue growth | Zydus Lifesciences | 29.0% |
No single name tops every row, which is exactly why a large-cap pharma stock comparison helps. Scale, returns, payouts and valuation each point to a different company, so decide what matters most to you before you rank the numbers.
What Is Driving Demand for Medicines at Home and Abroad Right Now?
Branded medicines, generics, biosimilars and active ingredients give large pharma companies several growth paths. Strong approvals and a global presence widen their reach. Knowing what moves launches and plant approvals helps you compare large-cap pharma stocks with the right questions in mind.
Product mix, research spend and approvals decide margins. Firms with a rising share of speciality and branded sales tend to earn more on each rupee of revenue. A good large-cap pharma stocks compared routine therefore tracks revenue, margins and approvals.
Risks to Weigh When You Compare Large-Cap Pharma Stocks
Pharma stocks depend on regulatory approvals, pricing in key markets, currency moves and research outcomes. Valuations are often rich, so read each filing for revenue, margin and pipeline commentary before you compare them. Every large-cap pharma stock comparison has blind spots, and for this group the biggest is launches and plant approvals.
Because revenue, margins and approvals drive these businesses, the most useful habit is to read the management commentary that comes with every result and note what is expected for the next quarter. Read together, the risk notes and the tables make this large-cap pharma stocks compared guide a balanced starting point.
How to Compare Large-Cap Pharma Stocks and Build a Shortlist
Start by deciding whether you want global generics, biosimilars or branded sales in India, because each responds to different triggers. Global makers reward readers who track approvals and launches, while domestic brand sellers reward those who track prescription growth. Done step by step, this large-cap pharma stocks compared routine becomes repeatable rather than a one-off exercise.
Then check valuation and returns, because premium multiples leave less room for slips and approvals can shift timing. Spreading your attention across one global maker and one domestic brand seller is a simple way to see both sides of the sector. Keep the shortlist of best large-cap pharma stocks short enough that you can actually follow each company’s quarterly results. When you compare large-cap pharma stocks again after new results, update only the rows that changed instead of starting over.
The Univest stock screener lets you filter large-cap pharma stocks by market capitalisation, return on equity and price to earnings, and the app keeps live prices a tap away through the trading day. Come back to this large-cap pharma stocks compared page after the next set of results to see which numbers have moved.
Check the Univest Screener for live large-cap pharma stock data
Download the Univest iOS App or Univest Android App to track these large-cap pharma stocks live.
Conclusion: Large-Cap Pharma Stocks Compared at a Glance
This large-cap pharma stocks compared review on price, valuation and Q2 FY27 results shows that no single name wins every measure. Zydus Lifesciences leads on size and Abbott India leads on return on equity, while the others bring their own strengths. Treat the large-cap pharma stocks Q2 FY27 results and large-cap pharma stocks valuation tables as a research starting point, then check the filings and speak to a SEBI-registered advisor before you invest. If you plan to compare large-cap pharma stocks again next quarter, the same checklist of price to earnings, return on equity and dividend yield will work.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Large-Cap Pharma Stocks Compared
Which are the top large-cap pharma stocks compared in this article?
Ans. The large-cap pharma stocks compared in this article are Dr Reddy’s Laboratories, Lupin, Zydus Lifesciences, Biocon and Abbott India. They are checked on previous close, market capitalisation, price to earnings, price to book, return on equity and the latest quarterly results, so you get a clear side-by-side starting point before you open any single company’s filings in more depth.
Which large-cap pharma stock has the highest market capitalisation?
Ans. Among the five names, Zydus Lifesciences has the highest market capitalisation at Rs 1,18,713 crore. Dr Reddy’s Laboratories follows at Rs 1,14,933 crore. Market capitalisation is the total value the market places on a company and moves with the share price every day, so check the live figure before you rely on it.
Which of these large-cap pharma stocks has the lowest price to earnings ratio?
Ans. On large-cap pharma stocks valuation, Lupin has the lowest price to earnings ratio among these large-cap pharma stocks at 17.70, based on the latest reported earnings. Biocon sits at the other end at 176.03. A lower multiple is not automatically better, since growth, margins and business quality all influence what investors are willing to pay.
Which large-cap pharma stock has the highest return on equity?
Ans. Abbott India reports the highest return on equity in this group at 38.71%. Return on equity shows how much profit a company earns on shareholder funds, so a higher figure usually points to efficient use of capital. Compare it over several years, and keep debt levels in mind, because heavy borrowing can lift the ratio.
How did large-cap pharma stocks perform in Q2 FY27 results?
Ans. Four of the five names have filed Q2 FY27 numbers in our data. Zydus Lifesciences recorded the fastest revenue growth at 29.0% year on year. For large-cap pharma stocks Q2 FY27 results, the others are covered on their latest reported quarter, and each filing on the exchange website carries the full detail.
What are the main risks when you compare large-cap pharma stocks?
Ans. Pharma stocks depend on regulatory approvals, pricing in key markets, currency moves and research outcomes. Valuations are often rich, so read each filing for revenue, margin and pipeline commentary before you compare them. Keep an eye on revenue, margins and approvals.
Which metrics matter most when you compare large-cap pharma stocks?
Ans. Revenue growth, operating margin, research spend and approvals matter most for operating performance. Price to earnings, price to book, return on equity and dividend yield show how the market values each company. Read each company’s filing for these along with the numbers in this article.
Which is the best large-cap pharma stock to buy among these five?
Ans. The best large-cap pharma stock depends on whether you value global generics, biosimilars or branded sales in India, because the five names differ on all three. On the numbers in this article, Zydus Lifesciences has the largest market capitalisation; Lupin has the lowest price to earnings; Abbott India has the highest return on equity as well as the highest dividend yield. No single stock tops every measure, and none of this is a recommendation. Use the tables to build a shortlist, check the latest filings, and speak to a SEBI-registered advisor before you decide, since your goals, time horizon and risk appetite matter more than any ranking.